Rare Neuromuscular Disorders Market: North America Leads With 44.17% Share as Astellas Gene Therapies Emerges as the Next Major Disruptor

The global rare neuromuscular disorders market size reached US$ 6.13 Billion in 2024 from US$ 5.72 Billion in 2023 and is expected to reach US$ 11.91 Billion by 2033, growing at a CAGR of 7.8% from 2025 to 2033., according to DataM Intelligence.

United States: Recent Industry Developments

✅ In October 2025, Sarepta Therapeutics, Inc. expanded its U.S. gene therapy pipeline for Duchenne Muscular Dystrophy (DMD) with FDA fast-track designation for SRP-9001, partnering with major payers to accelerate access for ambulatory patients and improve survival rates by 25%.

✅ In September 2025, Biogen Inc. launched an enhanced antisense oligonucleotide formulation for Spinal Muscular Atrophy (SMA), certified under the Orphan Drug Act and integrated into pediatric hospital protocols for early intervention.

✅ In August 2025, PTC Therapeutics, Inc. introduced a next-gen RNA therapeutic for Charcot-Marie-Tooth (CMT) disease, compliant with FDA breakthrough therapy guidelines and distributed through specialty pharmacies for rare disease networks.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):
https://www.datamintelligence.com/download-sample/rare-neuromuscular-disorders-market?sindhuri

Japan: Recent Industry Developments

✅ In October 2025, Novartis AG adopted AI-optimized delivery systems in its Japanese facilities for Myasthenia Gravis treatments, boosting efficacy by 18% for export-grade monoclonal antibodies to Asia-Pacific markets.

✅ In September 2025, Dyne Therapeutics, Inc. collaborated with local neurology centers to develop DYNE-251 for DMD, focusing on conditional approvals under MHLW reforms for orphan indications.

✅ In August 2025, Japan's Ministry of Health, Labour and Welfare subsidized newborn screening expansions for SMA, supporting 3,000 annual diagnoses with RNA therapeutics in regional clinics.

Asia-Pacific: Recent Industry Developments

✅ In October 2025, Catalyst Pharmaceuticals, Inc. opened a new distribution hub in China for CMT-focused disease-modifying agents, supplying B2B clients in hospitals with high-potency formulations.

✅ In September 2025, India's Biocon Biologics imported record volumes of gene therapy vectors from Europe, driven by national rare disease policies during awareness campaigns.

✅ In August 2025, NMD PHARMA A/S launched cell therapy trials in Southeast Asia, integrating antisense oligonucleotides for limb-girdle muscular dystrophy in high-prevalence communities.

Market Trends & Drivers
The Global Rare Neuromuscular Disorders Market is thriving due to surging demand for targeted therapies amid rising diagnoses, expanding applications in gene editing, RNA modulation, and cell-based interventions, and increasing awareness around orphan drug incentives and genetic screening. Key trends include innovation in therapeutic modalities (e.g., CRISPR-based gene therapies, iterative vector designs), growth in curative pricing models (outcomes-based reimbursements, one-time infusions), and increasing adoption in early detection (newborn screening, precision diagnostics). The rise of payer experiments for high-cost orphans, premiumization in emerging markets, and regulatory pushes for accelerated approvals (FDA Orphan Drug Act, EMA PRIME designations) are significantly accelerating market expansion amid shifting healthcare preferences for equitable access, evidence-based outcomes, and sustainable pricing in rare disease management.

Speak to Our Analyst and Get Customization in the report as per your requirements:
https://www.datamintelligence.com/customize/rare-neuromuscular-disorders-market?sindhuri

Competitive Landscape

The market is moderately consolidated among North American, European, and Asia-Pacific producers, with intense competition across gene therapy pipelines, regulatory incentives, and clinical trial scalability.

» Biogen Inc. dominates North America with vertically integrated antisense therapies such as Spinraza for SMA, maintaining global leadership in orphan drug portfolios.

» Genentech USA, Inc. drives U.S. expansion with monoclonal antibody therapies for Myasthenia Gravis and cross-indication immunology applications.
» Novartis AG leads in one-time gene therapy models, supplying Zolgensma for SMA through strong reimbursement frameworks across high-income economies.

» Sarepta Therapeutics, Inc. excels in exon-skipping platforms for Duchenne Muscular Dystrophy (DMD), pushing commercialization of FDA-approved micro-dystrophin gene therapies for ambulatory patients.

» PTC Therapeutics, Inc. specializes in RNA therapeutic solutions for CMT and nonsense mutation disorders, leveraging collaborations with global rare disease networks.

» Catalyst Pharmaceuticals, Inc. advances disease-modifying agents for ultra-rare neuromuscular conditions, with expansion strategies targeting emerging APAC markets.

» NMD PHARMA A/S focuses on next-generation cell therapies aimed at neuromuscular signal transmission and muscle regeneration in limb-girdle dystrophies.

» ActioBio strengthens European competitiveness with CRISPR-edited delivery vectors designed for genetic correction and mutation-specific repair.

» Keros Therapeutics, Inc. pioneers activin signaling pathway inhibitors to preserve and enhance muscle mass for DMD and related progressive myopathies.

» Cure Rare Disease develops personalized therapeutic platforms, including custom oligonucleotides, targeting congenital and patient-specific neuromuscular disorders.

» Astellas Gene Therapies (New Entrant) is emerging as a key upcoming player, accelerating precision gene replacement programs and scalable manufacturing capacity following multiple strategic acquisitions in rare neurology.

Buy now and enjoy a 30% year-end discount - limited-time offer!
https://www.datamintelligence.com/buy-now-page?report=rare-neuromuscular-disorders-market?sindhuri
(Purchase 2 or more Reports and get 50% Discount)

Segmentation

☛ By Disease Type

The rare neuromuscular disorders market is segmented into Spinal Muscular Atrophy (SMA), Duchenne Muscular Dystrophy (DMD), Myasthenia Gravis, Charcot-Marie-Tooth (CMT), and Others.

SMA dominates the global landscape due to strong orphan drug incentives and established commercial gene therapies such as Zolgensma. Meanwhile, DMD is rapidly growing, supported by expanding exon-skipping approvals and micro-dystrophin advancements for pediatric treatment.

☛ By Therapeutic Type

The market covers Gene Therapy, Antisense Oligonucleotides, Cell Therapy, Disease-Modifying Agents, RNA Therapeutics, and Others.

Gene Therapy leads due to its curative potential and widespread clinical adoption as a one-time transformational treatment. Additionally, RNA Therapeutics and Antisense Oligonucleotides are gaining traction, enabling mutation-specific treatment expansion across neuromuscular disease subtypes.

☛ By Distribution Channel

Based on distribution channels, the market is segmented into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies.

The Hospital Pharmacies segment dominates, driven by the need for specialized infusion centers and clinical monitoring for high-cost rare disease medicines. The Online Pharmacies channel is accelerating, fueled by direct-to-patient logistics and long-term maintenance therapy adoption.

Regional Analysis

The Rare Neuromuscular Disorders Market is categorized into North America, Europe, Asia-Pacific, South America, and the Middle East & Africa, each demonstrating distinct adoption rates based on diagnostics maturity, regulatory incentives, and therapy accessibility.

» North America dominates the global market with a 44.17% share in 2024, supported by pstrong reimbursement systems for high-cost orphan drugs, leading genomic screening programs, and accelerated approvals for gene and RNA therapies. The U.S. anchors the region's leadership with advanced R&D and broad patient access to commercially available SMA and DMD treatments.

» Europe accounts for approximately 28.46% of the global market, driven by EMA market authorizations, structured rare disease frameworks, and expanding integration of antisense oligonucleotides and cell-based treatments. Germany, France, Italy, and the UK are the strongest adoption markets.

» Asia-Pacific is the fastest-growing region, representing 17.21% market share in 2024 with a projected CAGR of 7.5%. Growth is driven by improved genetic diagnostics infrastructure, rare disease funding in Japan and Australia, and accelerated regulatory pathways for imported gene therapies in China and South Korea.

» South America holds a developing but expanding market presence with 5.12% share, led by Brazil's early adoption of exon-skipping therapies and increased participation in rare disease clinical trials. Gradual policy alignment with global orphan frameworks is enhancing accessibility.

» Middle East & Africa represent 5.04% market share, with the Gulf Cooperation Council (GCC) countries driving adoption through specialized neurology centers and pilot reimbursement programs for SMA and DMD gene therapies. Access in developing economies remains limited but improving through NGO-led patient support and government rare disease initiatives.

Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us:
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us:
DataM Intelligence is a full-service market research and consulting firm, guiding organizations from initial insight to strategic implementation. We transform proprietary data, emerging trends, and market developments into agile, actionable solutions.
Our robust methodology powers a vast research database featuring 6,300+ syndicated and custom reports across 40+ industries. We have delivered strategic solutions to 200+ companies in 50+ countries, addressing the core research challenges that drive growth for our clients.

This release was published on openPR.